MedPath

Patient Experiences and Perceptions of Living with Refractory Diabetes Mellitus with Insulin Resistance in Japan -A Qualitative Research

Not Applicable
Conditions
Insulin resistance, lipoatrophic diabetes mellitus
Registration Number
JPRN-UMIN000043693
Lead Sponsor
ippon Boehringer Ingelheim Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
4
Inclusion Criteria

Not provided

Exclusion Criteria

-Not eligible at physician's discretion -Patients currently participating in clinical trials on the efficacy and safety of empagliflozin for refractory diabetes mellitus with insulin resistance (conducted by Kobe University with funding and investigational drug provided by Nippon Boehringer Ingelheim [BI] [jRCT2051190029, jRCT2051190094])

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath